On Friday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s shares inclined 1.09% to $235.41.
Valeant Pharmaceuticals Intl Inc (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) recently declared that the European Commission has approved RELISTOR(R) (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The decision effective May 27, 2015 is applicable to all 28 European Union member states plus Iceland and Norway and comprises an additional one year of marketing protection. The European Commission decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which cited that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Questar Corporation (NYSE:STR)’s shares dropped -2.58% to $21.17.
Questar Corporation (STR) board of directors recently approved a $0.21 (21 cents) quarterly common stock cash dividend. The dividend, payable June 22, 2015, to shareholders of record on June 5, 2015, is the same as the previous quarter. This is the company’s 282nd successive dividend.
Questar Corporation operates as an integrated natural gas company in the United States. It distributes natural gas as a public utility in Utah, southwestern Wyoming, and a small portion of southeastern Idaho serving 962,225 sales and transportation customers; and owns and operates distribution systems comprising 28,239 miles of street mains, service lines, and interconnecting pipelines, in addition to has long-term franchises granted by communities and counties in its service area.
At the end of Friday’s trade, DDR Corp (NYSE:DDR)‘s shares dipped -1.31% to $16.54.
DDR Corp (DDR) will issue financial results for the quarter ended June 30, 2015 after the market closes on Wednesday, July 29, 2015. The Company will conduct a conference call and audio webcast on Thursday, July 30, 2015 at 10:00 a.m. ET.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
Exelixis, Inc. (NASDAQ:EXEL), ended its Friday’s trading session with 2.13% gain, and closed at $3.35.
Exelixis, Inc. (EXEL) declared positive results from a phase 2 clinical study evaluating cabozantinib as a treatment for EGFR wild-type non-small cell lung cancer (NSCLC). The trial, Study E1512, is a randomized phase 2 trial by the ECOG-ACRIN Cancer Research Group of cabozantinib and erlotinib, alone or in combination, as second- or third-line therapy in patients with metastatic EGFR wild-type NSCLC. Exelixis formerly declared positive top-line results from this trial in November 2014. Data from the trial will be presented recently during an oral presentation (Abstract #8003) at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held this week in Chicago, Illinois. Study chair Joel Neal, M.D., Ph.D., of ECOG-ACRIN’s Thoracic Cancer Committee and an Assistant Professor of Medicine (Oncology) at Stanford University/Stanford Cancer Institute will present the results.
Study E1512 met its primary endpoint, demonstrating noteworthy enhances in progression-free survival (PFS) for cabozantinib and the combination of cabozantinib plus erlotinib when individually contrast to the erlotinib arm. The median PFS for the combination of cabozantinib and erlotinib was 4.7 months as compared to 1.9 months for erlotinib alone, a more than two-fold enhance that corresponds to a 65% reduction in the risk of disease worsening (hazard ratio [HR]=0.35, 80% CI 0.23-0.52, p=0.0005). The median PFS for cabozantinib monotherapy was 4.2 months as compared to 1.9 months for erlotinib alone, a more than doubling that corresponds to a 62% reduction in the risk of disease worsening (HR=0.38, 80% CI 0.27-0.55, p=0.0004).
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
